Genetic Characterization of Trypanosoma cruzi I Populations from an Oral Chagas Disease Outbreak in Venezuela: Natural Resistance to Nitroheterocyclic Drugs.

The oral transmission of Chagas disease (oCD) in Venezuela announced its appearance in 2007. Different from other populations affected by oCD and despite close supervision during treatment with nitroheterocyclic drugs, the result was treatment failure. We studied genetic features of natural bloodstream parasite populations and populations after treatment of nine patients of this outbreak. In total, we studied six hemoculture isolates, eight Pre-Tx blood samples, and 17 samples collected at two or three Post-Tx time-points between 2007 and 2015. Parasitic loads were determined by quantitative polymerase chain reaction (qPCR), and discrete typing units (DTU), minicircle signatures, and Tcntr-1 gene sequences were searched from blood samples and hemocultures. Half-maximal inhibitory concentration (IC50) values were measured from the hemocultures. All patients were infected by TcI. Significant decrease in parasitic loads was observed between Pre-Tx and Post-Tx samples, suggesting the evolution from acute to chronic phase of Chagas disease. 60% of intra-DTU-I variability was observed between Pre-Tx and Post-Tx minicircle signatures in the general population, and 43 single-nucleotide polymorphisms (SNPs) were detected in a total of 12 Tcntr-1 gene sequences, indicative of a polyclonal source of infection. SNPs in three post-Tx samples produced stop codons giving rise to putative truncated proteins or displaced open reading frames, which would render resistance genes. IC50 values varied from 5.301 ± 1.973 to 104.731 ± 4.556 μM, demonstrating a wide range of susceptibility. The poor drug response in the Pre-Tx parasite populations may be associated with the presence of naturally resistant parasite clones. Therefore, any information that can be obtained on drug susceptibility from in vitro assays, in vivo assays, or molecular characterization of natural populations of Trypanosoma cruzi becomes essential when therapeutic guidelines are designed in a given geographical area.

[1]  A. Berenstein,et al.  Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults , 2022, Antimicrobial agents and chemotherapy.

[2]  A. Muñoz-Calderón,et al.  In vitro differentiation of Trypanosoma cruzi epimastigotes into metacyclic trypomastigotes using a biphasic medium , 2021, STAR protocols.

[3]  J. Ramirez,et al.  Ten-year follow-up of the largest oral Chagas disease outbreak. Laboratory biomarkers of infection as indicators of therapeutic failure. , 2021, Acta tropica.

[4]  A. Muñoz-Calderón,et al.  Characterization and Follow-Up of Trypanosoma cruzi Natural Populations Refractory to Etiological Chemotherapy in Oral Chagas Disease Patients , 2021, Frontiers in Cellular and Infection Microbiology.

[5]  H. H. Veloso,et al.  Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study , 2020, EClinicalMedicine.

[6]  T. Pumarola,et al.  Usefulness of real-time PCR during follow-up of patients treated with Benznidazole for chronic Chagas disease: Experience in two referral centers in Barcelona , 2020, PLoS neglected tropical diseases.

[7]  Awanish Kumar.  Survival Strategies of Leishmania Parasite: Too Many Questions and Few Answers , 2020, Current Pharmacology Reports.

[8]  M. Hecht,et al.  Correlation of Parasite Burden, kDNA Integration, Autoreactive Antibodies, and Cytokine Pattern in the Pathophysiology of Chagas Disease , 2019, Front. Microbiol..

[9]  A. Muñoz-Calderón,et al.  Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela , 2019, Journal of vector borne diseases.

[10]  David W. Gray,et al.  Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery , 2018, PLoS neglected tropical diseases.

[11]  A. Mejía-Jaramillo,et al.  Aldo‐keto reductase and alcohol dehydrogenase contribute to benznidazole natural resistance in Trypanosoma cruzi , 2017, Molecular microbiology.

[12]  R. López-Vélez,et al.  Drug resistance and treatment failure in leishmaniasis: A 21st century challenge , 2017, PLoS neglected tropical diseases.

[13]  B. Zingales.  Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. , 2017, Acta tropica.

[14]  S. Yusuf,et al.  Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. , 2017, Journal of the American College of Cardiology.

[15]  J. A. Suárez,et al.  Long-term comparative pharmacovigilance of orally transmitted Chagas disease: first report , 2017, Expert review of anti-infective therapy.

[16]  L. Herrera,et al.  Urban Trypanosoma cruzi Oral Transmission: from a Zoonotic Founder Focus to the Largest Microepidemic of Chagas Disease , 2016 .

[17]  R. Gürtler,et al.  Multiplex Real-Time PCR Assay Using TaqMan Probes for the Identification of Trypanosoma cruzi DTUs in Biological and Clinical Samples , 2015, PLoS neglected tropical diseases.

[18]  A. Muñoz-Calderón,et al.  Update on oral Chagas disease outbreaks in Venezuela: epidemiological, clinical and diagnostic approaches , 2015, Memorias do Instituto Oswaldo Cruz.

[19]  S. Ienne,et al.  ABCG-like transporter of Trypanosoma cruzi involved in benznidazole resistance: gene polymorphisms disclose inter-strain intragenic recombination in hybrid isolates. , 2015, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[20]  M. Miles,et al.  Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity , 2014, Memorias do Instituto Oswaldo Cruz.

[21]  E. Chatelain,et al.  Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development , 2014, Scientific Reports.

[22]  L. Leon,et al.  Benznidazole-resistance in Trypanosoma cruzi: Evidence that distinct mechanisms can act in concert , 2014, Molecular and biochemical parasitology.

[23]  A. Muñoz-Calderón,et al.  Oral transmission of Chagas disease: typing of Trypanosoma cruzi from five outbreaks occurred in Venezuela shows multiclonal and common infections in patients, vectors and reservoirs. , 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[24]  J. Ramírez,et al.  Analytical Performance of a Multiplex Real-Time PCR Assay Using TaqMan Probes for Quantification of Trypanosoma cruzi Satellite DNA in Blood Samples , 2013, PLoS neglected tropical diseases.

[25]  B. Hall,et al.  Benznidazole-Resistance in Trypanosoma cruzi Is a Readily Acquired Trait That Can Arise Independently in a Single Population , 2012, The Journal of infectious diseases.

[26]  A. Mejía-Jaramillo,et al.  Gene expression study using real-time PCR identifies an NTR gene as a major marker of resistance to benznidazole in Trypanosoma cruzi , 2011, Parasites & Vectors.

[27]  R. Favaloro,et al.  Molecular identification of Trypanosoma cruzi discrete typing units in end-stage chronic Chagas heart disease and reactivation after heart transplantation. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  J. A. Suárez,et al.  Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. , 2010, The Journal of infectious diseases.

[29]  S. Croft,et al.  In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. , 2009, Biomedica : revista del Instituto Nacional de Salud.

[30]  O. Yun,et al.  Feasibility, Drug Safety, and Effectiveness of Etiological Treatment Programs for Chagas Disease in Honduras, Guatemala, and Bolivia: 10-Year Experience of Médecins Sans Frontières , 2009, PLoS neglected tropical diseases.

[31]  M. T. Bahia,et al.  Trypanosoma cruzi: Induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection. , 2008, Experimental parasitology.

[32]  A. Romanha,et al.  Proteomic analysis of Trypanosoma cruzi resistance to Benznidazole. , 2008, Journal of proteome research.

[33]  D. Horn,et al.  A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes , 2008, Proceedings of the National Academy of Sciences.

[34]  J. Altcheh,et al.  Direct molecular profiling of minicircle signatures and lineages of Trypanosoma cruzi bloodstream populations causing congenital Chagas disease. , 2007, International journal for parasitology.

[35]  Rodolfo Viotti,et al.  Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment , 2006, Annals of Internal Medicine.

[36]  S. Goldenberg,et al.  Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. , 2006, Molecular and biochemical parasitology.

[37]  M. Tibayrenc,et al.  Lack of correlation between in vitro susceptibility to Benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease. , 2004, Experimental parasitology.

[38]  M. Ouellette.  Biochemical and molecular mechanisms of drug resistance in parasites , 2001, Tropical medicine & international health : TM & IH.

[39]  J. McKerrow,et al.  Upregulation of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi. , 2000, Journal of cell science.

[40]  L. Filardi,et al.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[41]  C. Brodskyn,et al.  Immunological response of Swiss mice to infection with three different strains of Trypanosoma cruzi. , 1985, Annals of tropical medicine and parasitology.

[42]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[43]  M. Ouellette,et al.  New mechanisms of drug resistance in parasitic protozoa. , 1995, Annual review of microbiology.